<h2>Question</h2>
<div class='specification'>
<p>Targeted Alpha Therapy (TAT) is a technique that involves using alpha-radiation to treat&nbsp;leukemia and other dispersed cancers.</p>
</div>

<div class='specification'>
<p>Yttrium-90 and lutetium-177 are used in radiotherapy.</p>
</div>

<div class='question' style='padding-left: 20px; padding-right: 20px;'>
<p>Explain why alpha-radiation is particularly suitable for this treatment.</p>
<div class='marks'>[2]</div>
<div class='question_part_label'>a.i.</div>
</div>
<div class='question' style='padding-left: 20px; padding-right: 20px;'>
<p>Outline how the alpha-radiation in TAT is directed to cancer cells.</p>
<div class='marks'>[1]</div>
<div class='question_part_label'>a.ii.</div>
</div>
<div class='question' style='padding-left: 20px; padding-right: 20px;'>
<p>Identify the type of radiation emitted by these two radioisotopes.</p>
<div class='marks'>[1]</div>
<div class='question_part_label'>b.i.</div>
</div>
<div class='question' style='padding-left: 20px; padding-right: 20px;'>
<p>State an equation for the one-step decay of yttrium-90.</p>
<div class='marks'>[1]</div>
<div class='question_part_label'>b.ii.</div>
</div>
<div class='question' style='padding-left: 20px; padding-right: 20px;'>
<p>The half-life of lutetium-177 is 6.75 days. Calculate the percentage remaining&nbsp;after 27 days.</p>
<div class='marks'>[1]</div>
<div class='question_part_label'>b.iii.</div>
</div>
<h2 style='margin-top: 1em'>Markscheme</h2>
<div class='question' style='padding-left: 20px;'>
<p>more damaging than other radiation types<br /><em><strong>OR</strong></em><br />very damaging to &laquo;cancer&raquo; cells<br /><em><strong>OR</strong></em><br />high ionizing density &laquo;of alpha particles&raquo;</p>
<p>absorbed within a very short range of emission<br /><em><strong>OR</strong></em><br />causes little damage to surrounding tissues</p>
<p>&nbsp;</p>
<p><em>Accept &ldquo;high ionizing power &laquo;of alpha&nbsp;particles&raquo;&rdquo; for M1.&nbsp;</em></p>
<p><em>Accept &ldquo;low penetrating power &laquo;of alpha particles&raquo;&rdquo; for M2.</em></p>
<p><strong><em>[2 marks]</em></strong></p>
<div class='question_part_label'>a.i.</div>
</div>
<div class='question' style='padding-left: 20px;'>
<p>&laquo;radioactive isotope/radionuclide/alpha-emitter&raquo; administered using carrier&nbsp;drug/protein/antibodies</p>
<p><em><strong>[1 mark]</strong></em></p>
<div class='question_part_label'>a.ii.</div>
</div>
<div class='question' style='padding-left: 20px;'>
<p>beta/&beta; &laquo;radiation&raquo;</p>
<p><em><strong>[1 mark]</strong></em></p>
<div class='question_part_label'>b.i.</div>
</div>
<div class='question' style='padding-left: 20px;'>
<p>\({}_{39}^{90}Y \to {}_{40}^{90}Zr + \beta \)</p>
<p>&nbsp;</p>
<p><em>Accept "</em>\(_{ - 1}^{\;\,0}e/e/{e^ - }\)<em>" <strong>OR</strong> "</em>\(_{ - 1}^{\;\,0}\beta /{\beta ^ - }\)<em>"</em></p>
<p><em>Accept ECF from (b) (i) if incorrect&nbsp;radiation identified, eg, </em>\(_{39}^{90}Y \to _{37}^{86}Rb + _2^4He\)</p>
<p><strong><em>[1 mark]</em></strong></p>
<div class='question_part_label'>b.ii.</div>
</div>
<div class='question' style='padding-left: 20px;'>
<p><strong>ALTERNATIVE 1:</strong><br />&laquo;4 half-lives&raquo;<br />6.25 &laquo;%&raquo;</p>
<p><strong>ALTERNATIVE 2:</strong><br />&laquo;<em>N<sub>t</sub></em> =&nbsp;<em>N<sub>0</sub></em>\({\left( {0.5} \right)^{\frac{t}{{{t_{1/2}}}}}} = 100{\left( {0.5} \right)^{\frac{{27}}{{6.75}}}} = \)&raquo; 6.25 &laquo;%&raquo;</p>
<p><em><strong>[1 mark]</strong></em></p>
<div class='question_part_label'>b.iii.</div>
</div>
